Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations
https://www.facingourrisk.org/research-clinical-trials/study/152/talazoparib-in-treating-patients-with-recurrent-advanced-or-metastatic-cancers-and-inherited-or-acquired-gene-mutations
Clinicaltrials.gov identifier:
NCT02286687 (https://clinicaltrials.gov/show/NCT02286687)
Study Contact Information:
Contact: Dr. Sarina A. Piha-Paul by phone: 713-563-1930 or email
About the Study
This study will look at how well the PARP inhibitor talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have inherited mutations or tumor mutations in BRCA or other specific genes. NOTE: This study is no longer enrolling patients.
Type of Study
This is an open-label, single arm study.
- In an open-label study, participants will know which medication they are receiving.
- In a single-group assignment study, all study participants will receive the same therapy.
What the Study Entails
- Participants will receive talazoparib orally once per day. Participants will remain on the medication as long as their cancer doesn't progress and they don't experience unacceptable side effects.
- Participants are followed up at 30 days and then every 12 weeks for 1 year.
Study Site
Houston, TX
M D Anderson Cancer Center
Contact: Dr. Sarina A. Piha-Paul by phone: 713-563-1930
This Study is Open To:
NOTE: This study is no longer enrolling patients.
This Study is Not Open To:
NOTE: This study is no longer enrolling patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.